The Conversation (0)
(TheNewswire)
Calgary, AB TheNewswire - October 19, 2021 Universal Ibogaine Inc. (TSXV:IBO) ("Universal Ibogaine", "UI" or the "Company"), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, is pleased to announce an expansion of its Board of Directors and welcomes two seasoned public company Board veterans, Anthony DeCristofaro and David Danziger, to fill two current Board vacancies.
Anthony DeCristofaro
Mr. DeCristofaro is currently CEO of Qnext Corp., a global developer of disruptive apps and private cloud technologies, and his extensive experience includes thirty years in the computer industry and three M&A transactions valued at more than $600 million. Over the course of his career, DeCristofaro has been sought out as a member of several high-profile public Boards, including Hartco, Delrina, Synchronica, and TransGaming. He also currently serves on the Board of Directors of Jack Nathan Medical Corp.
Previously he was President and CEO of iseemedia Inc. which merged with Synchronica in 2010, and was also CEO and founder of MGI Software Corp. ("MGI"). Anthony has an international business and technology background, building disruptive technologies into best-in-category companies for more than 30 years. DeCristofaro steered MGI's market cap value on the TSE to over $1 billion, and later merged MGI with Roxio in 2002. Prior to MGI Mr. DeCristofaro was a founding board member of Delrina and Vice President/General Manager of AST Canada, in addition to founding computer equipment manufacturer NEC Canada.
David Danziger, CPA, CA
David Danziger is Senior Vice President, Assurance & National Leader, Public Companies of MNP LLP, Chartered Professional Accountants ("MNP"), Canada's fifth largest accounting firm. He is a member of the firm's management team and responsible for providing leadership and direction to MNP's Assurance practice across Canada. David has extensive experience in both Canada and USA public market transactions and leverages significant expertise, having served as a director on many public companies listed on the TSX, the TSX Venture, the CSE and the New York Stock Exchange.
Mr. Danziger serves in both the audit function and as a compliance adviser to various public companies, and private firms looking to go public in Canada and in the USA. David has spent the last 18 years almost exclusively working with public company clients in a variety of industries, and advising on numerous complex and public market transactions, regulatory issues, and prospectus filings.
Mr. Danziger has extensive experience as a director of public companies, including serving in roles as Board Chairman and as Chairman of Audit Committees. His past Board roles include Minacs Worldwide (TSX), Gamesys PLC (LSE), The Intertain Group (TSX), American Apparel (NYSE), Integrity Gaming (TSXV), Eurotin Inc. (TSXV) and Euro Sun Mining (TSX).
Mr. Danziger is a past member of the Ontario Securities Commission's Advisory Committee for Small to Medium Sized Enterprises, assisting in advising on potential future policies affecting the publicly traded markets in Ontario. He is also a member of the Advisory Committee to the TSXV.
From Dr. Rami Batal, UI's Chief Executive Officer:
"We are excited to have attracted Anthony and David to join our Board, as they have extensive public company Board, corporate finance and capital markets experience, as well as success in advising and building start-up entities. We look forward to drawing on their expertise, which will include David serving as Chair of UI's Audit Committee."
About Universal Ibogaine Inc.
UI is a life sciences company, with a goal to develop a platform of addiction treatment clinics, which may eventually use ibogaine as a primary modality for the interruption and ideally cessation of addictions to primarily opioids such as oxycodone, heroin, fentanyl , as well as alcohol, cocaine, and other stimulants.
UI separately plans to clinically develop ibogaine, a natural plant substance, as an authorized addiction interruption medicine for the treatment of Opioid Use Disorder. A Clinical Trial Application to Health Canada is being developed to undertake clinical trials in Canada, aimed at proving the safety and efficacy of the use of ibogaine for this purpose. In the longer term, UI plans to introduce ibogaine into the addiction treatment protocols to be used in its' future facilities.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such as "plans", "expect", "project", "intend", "will", "believe", "anticipate", "estimate", "scheduled", "potential", or other similar words, or statements that certain events or conditions "may", "should" or "could" occur. The forward-looking statements and information are based on certain key expectations and assumptions made by UI. Although UI believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because UI can give no assurance that they will prove to be correct.
Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks, which include, but are not limited to, risks that required regulatory approvals are not obtained. The reader is cautioned that assumptions used in the preparation of such information, although considered reasonable by UI at the time of preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on forward-looking information, which speaks only to conditions as of the date hereof. UI does not undertake any obligation to release publicly any revisions to forward-looking information contained herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.
For further information:
Investor Relations: Dugan Selkirk - IR Manager
dugan.selkirk@universalibogaine.com
Media Contact: Cathy Fernandes -VP, Marketing & Communications cathy.fernandes@universalibogaine.com
https://universalibogaine.com
Copyright (c) 2021 TheNewswire - All rights reserved.
Figure one: Individual patient (001-005) and pooled results highlighting improvements in fibromyalgia domains as presented by University of Michigan 9 August 2024 (adapted)
Figure two: Individual patient and pooled results as presented by University of Michigan 9 August 2024 (adapted)
